Interim CEO Magda Jonikas describes Mosaic's platform and the rationale behind these two targets the company has licensed in.

CEO Alan Rigby talks about the work Epitopia does finding "Crypotgen" antigens for its own off-the-shelf cancer vaccines, and discusses what was appealing to Merck about the partnership.

Co-Founder and CEO Dominik Schumacher describes what he thinks can be improved on from the current generation of antibody-drug conjugates, and the science behind how Tubilis is designing its ADCs differently. He highlights the company's clinical Napi2b and 5T4 programs.

CEO Niall Martin walks us through the current state of this corner of drug development, and then highlights data presented at AACR last week for its ATR kinase inhibitor. As he describes, patient selection for these therapies can make a big difference.

CEO Andrew Cavey describes how ITM has been investing to avoid the shortages others have experienced, and explains how the supply chain works for radiopharmaceuticals. He walks us through the science behind these medicines before highlighting ITM's pipeline.

CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation, and also the clinical experience so far on the lead program in asthma.

CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47 or CD28 backbone.

Co-Founder and CEO Pierluigi Paracchi describes the terms of the convertible bond raise, which gives the investor, ENEA Tech and Biomedical, the opporutnity to convert to equity in three years. He also provides an update on the progress of dosing renal cell carcinoma patients in the clinic, and what we can expect from the trial throughout the rest of the year.

Chairman & CEO Emmanuel Savioz describes the benefits of decentralized manufacturing that is at or near the site of treatment. He highlights an armored-CAR AML program the company has with MSK in New York, and discusses Tigen's non-viral platform for NHL and multiple myeloma.

CEO Klaus Dugi describes why the company is focused on mitochondria and how it using small molecules to fix them. He covers the three main disease areas Vandria is focused on, including a clinical program in mild cognitive impairment.